Treatment of neurological injury by administration of human umbilical cord tissue-derived cells
View Patent ↗Methods, pharmaceutical compositions and kits for regenerating or repairing neural tissue, decreasing apoptosis and improving neurological function following injury using human umbilical cord tissue-derived cells are disclosed.
1. A method of treating a patient having a neurological injury comprising administering to the patient isolated umbilical cord tissue-derived cells in an amount effective to treat the neurological injury, wherein the neurological injury is cerebral hemorrhage, cerebral ischemia or traumatic brain injury, and wherein the umbilical cord tissue-derived cells are derived from human umbilical cord tissue substantially free of blood, are capable of self-renewal and expansion in culture, have the potential to differentiate into cells of at least a neural phenotype, and do not express CD117.
2. The method of claim 1 , wherein the cells are administered with at least one other cell type.
3. The method of claim 2 , wherein the other cell type is an astrocyte, oligodendrocyte, neuron, neural progenitor, neural stem cell or other multipotent or pluripotent stem cell.
4. The method of claim 1 , wherein the umbilical cord tissue-derived cells are administered at a pre-determined site in the central nervous system of the patient.
5. The method of claim 1 , wherein the umbilical cord tissue-derived cells are administered by injection or infusion.
6. The method of claim 1 , wherein the umbilical cord tissue-derived cells further express CD10, CD13, CD44, CD73, CD90, PDGFr-alpha and HLA-A, B, C.
7. The method of claim 1 , wherein the umbilical cord tissue-derived cells further do not express CD31, CD34, CD45, CD141 and HLA-DR, DP, DQ.
8. The method of claim 1 , wherein the neurological injury is cerebral hemorrhage.
9. The method of claim 1 , wherein the neurological injury is cerebral ischemia.
10. The method of claim 1 , wherein the neurological injury is traumatic brain injury.
11. A method of stimulating regeneration capacity of a subventricular zone of a patient following traumatic brain injury comprising administering to the patient isolated umbilical cord tissue-derived cells in an amount effective to increase neurogenesis, angiogenesis, or synaptogenesis, wherein the umbilical cord tissue-derived cells are derived from human umbilical cord tissue substantially free of blood, are capable of self-renewal and expansion in culture, have the potential to differentiate into cells of at least a neural phenotype, and do not express CD117.
12. The method of claim 11 , wherein the umbilical cord tissue-derived cells are administered with at least one other cell type.
13. The method of claim 12 , wherein the other cell type is an astrocyte, oligodendrocyte, neuron, neural progenitor, neural stem cell or other multipotent or pluripotent stem cell.
14. The method of claim 11 , wherein the cells are administered at a pre-determined site in the central nervous system of the patient.
15. The method of claim 11 , wherein the cells are administered by injection or infusion.
16. The method of claim 11 , wherein the umbilical cord tissue-derived cells further express CD10, CD13, CD44, CD73, CD90, PDGFr-alpha and HLA-A, B, C.
17. The method of claim 11 , wherein the umbilical cord tissue-derived cells further do not express CD31, CD34, CD45, CD141 and HLA-DR, DP, DQ.